<DOC>
	<DOCNO>NCT00520000</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy paclitaxel albumin-stabilized nanoparticle formulation carboplatin work different way stop growth tumor cell , either kill cell stop divide . Giving paclitaxel albumin-stabilized nanoparticle formulation together carboplatin may kill tumor cell . PURPOSE : This phase I trial study side effect , best way give , best dose paclitaxel albumin-stabilized nanoparticle formulation give together carboplatin treat patient advanced metastatic solid tumor .</brief_summary>
	<brief_title>Carboplatin Paclitaxel Albumin-Stabilized Nanoparticle Formulation Treating Patients With Advanced Metastatic Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) paclitaxel albumin-stabilized nanoparticle formulation give weekly 3 week administer carboplatin give every 4 week . - Determine MTD paclitaxel albumin-stabilized nanoparticle formulation give every 3 week administer carboplatin give every 3 week . - Determine MTD paclitaxel albumin-stabilized nanoparticle formulation give week 1 2 administered carboplatin give every 3 week . - Evaluate sequence-dependent effect toxicity pharmacokinetics combination paclitaxel albumin-stabilized nanoparticle formulation carboplatin . Secondary - Explore antitumor activity paclitaxel albumin-stabilized nanoparticle formulation give weekly every 3 week . OUTLINE : Patients assign 1 3 treatment arm . - Arm I : Patients receive carboplatin IV 30 minute day 1 paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 , 8 , 15 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . - Arm II : Patients receive carboplatin IV 30 minute day 1 paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . - Arm III : Patients receive carboplatin IV 30 minute day 1 paclitaxel albumin-stabilized nanoparticle formulation IV 30 minute day 1 8 . Treatment repeat every 21 day 6 course absence disease progression unacceptable toxicity . Patients arm I II undergo blood sample collection periodically pharmacokinetic study . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Histologically cytologically confirm solid tumor Advanced metastatic disease Measurable evaluable disease Must meet 1 follow criterion : Failed standard therapy Not candidate standard therapy Have disease define standard therapy Exclusion criterion : Symptomatic brain metastasis PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 Life expectancy ≥ 8 week Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 8.0 g/dL Total bilirubin normal Serum creatinine normal OR creatinine clearance ≥ 60 mL/min AST ALT ≤ 2.5 x upper limit normal Negative pregnancy test Exclusion criterion : Pregnant lactate Prior anaphylactic reaction severe allergic reaction paclitaxel and/or docetaxel Active infection require treatment antibiotic &gt; 4 week Uncontrolled congestive heart failure Symptomatic coronary artery disease heart block Myocardial infarction within past 3 month Peripheral neuropathy ≥ grade 2 cause PRIOR CONCURRENT THERAPY : No prior chemotherapy , radiotherapy , therapy malignancy within past 3 week No concurrent filgrastim , pegfilgrastim , sargramostim first course therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>